

14 November 2022

ASX Announcement

Firebrick CFO and Accounting Change

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) advises that Ms Kyla Garic has resigned her position as Chief Financial Officer (CFO). and through her company, Onyx Corporate, the provision of accounting and bookkeeping services for Firebrick, with an effective date of 25 January 2023.

The Company is pleased to advise that Mr Kavi Bekarma will take over the CFO duties and through his company, TripleEight Corporate, the provision of accounting and bookkeeping services for the Company from 1 December 2022 to allow for a smooth handover before 25 January 2023.

Kavi Bekarma is the Managing Director of TripleEight Corporate, a corporate accounting firm offering various services for listed and non-listed companies in the mining, oil and gas, technology and biotechnology sectors. Mr Bekarma is a Chartered Accountant of Australia and New Zealand, holds a Masters of Professional Accounting and a Bachelor's Degree in Management with Information Systems.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also now has a third patent family covering the Nasodine formulation. Firebrick is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com